English 
Japanese 
November 18, 2025
Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
Read More
November 14, 2025
PRISM BioLab Announces Achievement of Initial Milestone and Receipt of Upfront Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
PRISM BioLab is pleased to announce that we have achieved the initial milestone in our drug...
Read More
November 6, 2025
PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical
PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of...
Read More
October 21, 2025
Eisai to Present Clinical Trial and Biomarker Exploration Results of E7386, Co-Created with PRISM BioLab, at the ESMO Annual Congress
TOKYO, Japan, October 17, 2025: -- PRISM BioLab announces that Eisai Co., Ltd. will present clinical...
Read More
October 3, 2025
PRISM BioLab Announces Patent Grant for Novel Bicyclic PepMetics® Compounds
PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on...
Read More
October 3, 2025
Notice of Termination of Collaboration and Licensing Agreement with Servier
We would like to announce that PRISM BioLab and Servier have mutually agreed to terminate the...
Read More
August 2, 2025
Notice of Termination of Collaboration and Licensing Agreement with Eli Lilly and Company
We would like to announce that PRISM BioLab and Eli Lilly and Company have mutually agreed...
Read More
June 9, 2025
PRISM BioLab Announces Patent Acquisition for PepMetics® Technology Library Compounds
PRISM BioLab is pleased to announce that we obtained a patent for our novel compound library...
Read More
May 23, 2025
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
TOKYO, Japan, 23 May 2025: -- PRISM BioLab, Co. Ltd. , a leading discovery and development...
Read More
May 14, 2025
Announcement: Investor Relations Seminar for Individual Investors
CEO Dai Takehara will participate in the "103rd IR Seminar for Individual Investors" hosted by Logmi...
Read More